Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

NCT ID: NCT01363037

Last Updated: 2015-09-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-11-30
• Study Completion Date: 2012-08-31

Brief Summary

The purpose of this study is to assess the pharmacokinetics of the combination dapivirine and maraviroc vaginal ring and determine whether it is safe when used continuously for 28 days by healthy women in the United States.

Conditions

HIV Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Dapivirine-Maraviroc Vaginal Ring

Group Type: EXPERIMENTAL

Dapivirine-Maraviroc Vaginal Ring

Intervention Type: DRUG

dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days

Placebo Vaginal Ring

Group Type: PLACEBO_COMPARATOR

Placebo Vaginal Ring

Intervention Type: OTHER

dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days

Maraviroc Vaginal Ring

Group Type: ACTIVE_COMPARATOR

Maraviroc Vaginal Ring

Intervention Type: DRUG

dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days

Dapivirine Vaginal Ring

Group Type: ACTIVE_COMPARATOR

Dapivirine Vaginal Ring

Intervention Type: DRUG

dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days

Interventions

Dapivirine Vaginal Ring

dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days

Intervention Type: DRUG

Maraviroc Vaginal Ring

dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days

Intervention Type: DRUG

Placebo Vaginal Ring

dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days

Intervention Type: OTHER

Dapivirine-Maraviroc Vaginal Ring

dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age 18 through 40 years (inclusive) at screening, verified per site SOPs
• Able and willing to provide written informed consent to be screened for and take part in the study
• Able and willing to provide adequate locator information, as defined by the site SOPs
• HIV-uninfected, based on testing performed by study staff at Screening and Enrollment (per applicable algorithm in Appendix II)
• In general good health at Screening and Enrollment, as determined by the site IoR or designee
• At Screening, participant states willingness to abstain from receptive sexual activity (including oral, vaginal and anal intercourse) for the 14 days prior to enrollment and for the duration of study participation
• Per participant report, using an effective method of contraception at Enrollment, and intending to continue use of an effective method for the duration of study participation. Effective methods include hormonal methods (except contraceptive vaginal rings), intrauterine device (IUD) inserted at least 28 days prior to enrollment, being a woman who identifies as a woman who has sex with women exclusively, sterilization, and/or sexually abstinent for the past 90 days
• Satisfactory Pap result in the 12 calendar months prior to Enrollment consistent with Grade 0 according to the Female Genital Grading Table for Use in Microbicide Studies Addendum 1 to the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009), or satisfactory evaluation with no treatment required of Grade 1 or higher Pap result per American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines in the 12 calendar months prior to Enrollment.
• Per participant report at Screening and Enrollment, agrees not to participate in other research studies involving drugs, medical devices, or vaginal products for the duration of study participation
• Per participant report at Screening, regular menstrual cycles with at least 21 days between menses (does not apply to participants who report using a progestin-only method of contraception at screening, e.g., Depo-Provera or levonorgestrel-releasing IUD)
• At Screening and Enrollment, participant states a willingness to refrain from inserting any non-study vaginal products or objects into the vagina, including but not limited to, spermicides, female condoms, diaphragms, contraceptive vaginal rings, vaginal medications, menstrual cups, cervical caps (or any other vaginal barrier method), douches, lubricants, sex toys (vibrators, dildos, etc.), and tampons for the 5 days prior to enrollment throughout the duration of study participation. -- Note: At the Screening visit participant also agrees to refrain from the practices listed above for at least 5 days prior to enrollment.

Exclusion Criteria

• Participant report of any of the following at Screening:

• Known adverse reaction to silicone, titanium dioxide, or to any of the components of the study products
• Use and/or anticipated use during the period of study participation of CYP3A inducer(s) and/or inhibitor(s)
• Chronic and/or recurrent candidiasis
• Non-therapeutic injection drug use in the 12 months prior to screening
• Post-exposure prophylaxis for HIV exposure within 6 months prior to screening
• Last pregnancy outcome 90 days or less prior to screening
• Currently breastfeeding
• Hysterectomy
• Intends to become pregnant within the next 4 months
• Has plans to relocate away from the study site area in the next 4 months
• Reports participating in any other research study involving drugs, medical devices, or vaginal products 60 days or less prior to enrollment
• At Screening or Enrollment, as determined by the IoR/designee, any significant uncontrolled active or chronic cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder or infectious disease, or at increased risk of cardiovascular events
• Has any of the following laboratory abnormalities at Screening:

• Aspartate aminotransferase (AST) or alanine transaminase (ALT) Grade 1 or higher as per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0, December, 2004 (Clarification dated August 2009)
• Calculated creatinine clearance less than 60 mL/min by the Cockcroft- Gault formula, where creatinine clearance (female) in mL/min = (140 - age in years) x (weight in kg) x (0.85)/72 x (creatinine in mg/dL)
• Hemoglobin Grade 1 or higher as per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0, December, 2004 (Clarification dated August 2009)
• Platelet count Grade 1 or higher as per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0, December, 2004 (Clarification dated August 2009) --- Note: Otherwise eligible participants with an exclusionary test result may be retested during the screening process. If a participant is re- tested and a nonexclusionary result is documented within 45 days of providing informed consent for screening, the participant may be enrolled.
• At Screening or Enrollment, is pregnant
• Diagnosed with urinary tract infection (UTI) at Screening or Enrollment

-- Note: Otherwise eligible participants diagnosed with UTI during screening will be offered treatment and may be enrolled after completing treatment and all symptoms have resolved. If treatment is completed and symptoms have resolved within 45 days of obtaining informed consent for screening, the participant may be enrolled.

• Diagnosed with pelvic inflammatory disease, a sexually transmitted infection (STI) or reproductive tract infection (RTI) requiring treatment per current Centers for Disease Control and Prevention (CDC) guidelines (http://www.cdc.gov/std/treatment/) at Screening or Enrollment

-- Note: Otherwise eligible participants diagnosed with STI or RTI during screening will be offered treatment and may be enrolled after completing treatment and all symptoms have resolved. If treatment is completed and symptoms have resolved within 45 days of obtaining informed consent for screening, the participant may be enrolled.

• At Screening or Enrollment, has a clinically apparent Grade 1 or higher pelvic exam finding (observed by study clinician or designee) per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009), Addendum 1, Female Genital Grading Table for Use in Microbicide Studies

-- Note: Cervical friability bleeding associated with speculum insertion and/or specimen collection judged to be within the range of normal according to the clinical judgment of the IoR/designee is considered expected non-menstrual bleeding and is not exclusionary.

• At Screening, severe pelvic relaxation such that either the vaginal walls or the uterine cervix descend beyond the vaginal introitus with valsalva maneuver
• Has any other condition that, in the opinion of the IoR/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

International Partnership for Microbicides, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Beatrice A Chen, MD, MPH

Role: STUDY_CHAIR

University of Pittsburgh

Lori Panther, MD, MPH

Role: STUDY_CHAIR

The Fenway Institute

Locations

University of Alabama at Birmingham

Birmingham, Alabama, United States

The Fenway Institute/Fenway Community Health

Boston, Massachusetts, United States

Magee-Womens Hospital of UPMC

Pittsburgh, Pennsylvania, United States

Countries

United States

References

Chen BA, Panther L, Marzinke MA, Hendrix CW, Hoesley CJ, van der Straten A, Husnik MJ, Soto-Torres L, Nel A, Johnson S, Richardson-Harman N, Rabe LK, Dezzutti CS. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):242-9. doi: 10.1097/QAI.0000000000000702.

Reference Type: BACKGROUND

PMID: 26034880 (View on PubMed)

Other Identifiers

MTN-013/IPM 026

Identifier Type: -

Identifier Source: org_study_id